Celularity Inc. 8-K Summary: Annual Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of Celularity Inc.'s Annual Meeting of Stockholders held on December 19, 2025. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Florham Park, New Jersey. The filing details the voting outcomes for three specific proposals presented to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
Three proposals were voted upon at the Annual Meeting:
- Proposal 1 (Director Elections): Stockholders elected three Class I Directors to serve until 2028. However, a significant portion of votes were withheld for each nominee:
- Peter Diamandis, M.D.: 4,710,208 votes For; 9,890,022 votes Withheld.
- Diane Parks: 4,577,494 votes For; 10,022,736 votes Withheld.
- Geoffrey Ling, M.D.: 5,094,809 votes For; 9,505,421 votes Withheld.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- Result: Approved (10,050,276 For vs. 31,337 Against).
- Proposal 3 (Equity Plan Amendment): Stockholders voted on an amendment to the 2021 Equity Incentive Plan to increase the share reserve by 3,500,000 shares.
- Result: Not Approved (4,342,023 For vs. 890,138 Against).
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the implication of shareholder dissatisfaction indicated by the high number of votes withheld for directors and the rejection of the equity plan amendment. The filing notes that detailed descriptions of the proposals are available in the definitive proxy statement on Schedule 14A filed on November 7, 2025.
Investor Verification Checklist
- Verify the reasons for the high number of votes withheld for all three director nominees (over 9.5 million votes withheld for each).
- Review the Schedule 14A proxy statement to understand the specific terms of the rejected 2021 Equity Incentive Plan amendment.
- Confirm the Company's plan to address the rejection of the equity plan amendment and potential impacts on future employee compensation.
- Monitor for any follow-up communications from management regarding the director election results.